In order to investigate purin and primidin metabolism pathways in hepatitis, adenosine deaminase (ADA) and guanosine deaminase (GDA) activities in sera of patients with different types and manifestations of viral hepatitis disease (A, B, C, D, E, chronic, acute) 
Adenosine deaminase (ADA, adenosine aminohydrolase, E.C.3.5.4.4.) is an enzyme involved in the catabolism of purine bases, capable of catalysing the deamination of adenosine, forming inosine in the process (Fox & Kelly 1978) . ADA activity is widely distributed in human tissues and is higher in lymphoid tissues, and principal biological activity of ADA is detected in T lymphocytes (Sullivan et al. 1977) . Its main physiologic activity is related to lymphocytic proliferation and differentiation. As a marker of cellular immunity, its plasma activity is found to be elevated in diseases in which there is a cell-mediated immune response (Galanti et al. 1981 , Piras et al. 1982 . It was reported that high serum ADA activities were observed in patients with acute hepatitis, alcoholic hepatic fibrosis, chronic active hepatitis, liver cirrhosis and hepatoma (Kobayashi et al. 1993 ).
Guanosine deaminase (GDA, guanosine aminase, E.C. 3.5.4.15) catalyses the formation of xanthosine from guanosine, and is also widely distributed in human tissues (Bairoch 1996) .
Hepatitis can be described as an inflammatory process in the liver charactherized by diffuse or patchy hepatocellular necrosis affecting all acini. Hepatitis A virus (HAV) has no known chronic carrier state and plays no role in the production of chronic active hepatitis or cirrhosis. However, prognosis and outcome of acute hepatitis B infection are variable. As a result of subclinical infection, chronic infection occurs frequently in 10% of infected individuals (Robinson 1995) . In general, it is believed that immune system mediated processes play role in the pathogenesis of hepatitis B infection. The mechanisms involved in liver cell injury may be an HLA class I restricted cytotoxic T-cell response directed at HBcAg/HBeAg on hepatitis B virus (HBV)-infected hepatocytes, direct cytopathic effect of HBcAg expression in infected hepatocytes in hepatitis, a direct toxic effect of HBV on liver cells, liver cell injury results from high-level expression and inefficient secretion of HBsAg, and finally co-infection with a second cytopathic virus, the hepatitis delta virus (HDV). During HDV infection, many mechanisms may involve in the development of liver lesions as described for HBV.
As to hepatitis C virus (HCV), the pathogenesis is still to be excluded. Infection with HCV tends to become persistent in most of the infected individuals, apparently reflecting an inability of the immune system to mount an effective antiviral response (Alter et al. 1992) .
It is likely that most of hepatitis E virus (HEV) infections are immunopathologic in nature, as with other forms of acute viral hepatitis. Most often, the disease is self-limited. As is the case with hepatitis A, there is no progression to chronic hepatitis, no late hepatic sequel, and no evidence for persistent HEV infection (Brown et al. 1994) .
Since relationship exists between ADA activity and the cell mediated immune response, and there is not enough data about ADA and GDA activities in hepatitis due to different viral pathogens, we aimed to determine serum activities of these enzymes in patients with hepatitis and compare with the control group.
MATERIALS AND METHODS

Subjects -
The groups of patients were from Firat Medical Centre in Elazig where hepatitis is endemically present. Subjects were 103 patients divided into four groups with regard to their diagnosis as hepatitis A group (n=13), acute cases of hepatitis B (n=24), chronic cases of hepatitis B (n=49) and the group of other hepatitis types-C, D, E (n=17). As a control group, 52 healthy individuals aged 17-47 years from the same area were recruited. Ethical consents were obtained from all participants of this study. Clinical diagnosis of patients was confirmed by serological tests, biopsy specimens and other clinical findings.
Measurement of serum ADA activity -Ten ml of venous blood were withdrawn and transferred into dry tubes. Having centrifuged at 400 x g for 5 min, serum was separated for serum ADA activity assessment. Serum ADA activity was determined at 37 o C by a method described by Giusti and Galanti (1984) that was based on the Bertholet reaction. In brief, the formation of colored indophenol complex from ammonia liberated from adenosine and quantified spectrophotometrically. One unit of ADA is defined as the amount of enzyme required to release 1µmol of ammonia/min from adenosine at standard assay conditions. Results were expressed as international unit (IU) of enzyme activity of serum.
Measurement of serum GDA activity -GDA activity was measured as described. Ammonia formed during 30 min incubation at 37 o C in the presence of guanine in a phosphate buffer (pH 7.4) is estimated colorimetrically using a modified phenol-alkaline hypochlorite procedure (Caraway 1966) .
Measurement of serum aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels -Enzymes required to evaluate the liver function tests were performed by using colorimetric techniques with kit assay systems (Randox, Japan) in Olympus AO 600 autoanalyser system (Olympus, Japan), and performed as described by manufacturers.
Statistical analysis -Student's t test, MannWhitney U and Kruskal-Wallis tests were performed, using a computer program named SPSS for Windows Release 6.0.
RESULTS
The comparison of enzymatic levels in the sera of viral hepatitis cases with the control group is shown in the Table. All the enzymes, including ADA and GDA enzyme activities, were found to be significantly higher in the cases with hepatitis than the controls (p<0.01).
For the comparison of enzymatic levels in the sera of hepatitis cases divided into four different groups with regard to their clinical and serological features, such as acute hepatitis A and B, chronic hepatitis B, hepatitis A and other forms of hepatitis. Then, Kruskal-Wallis test was carried out amongst one another. Results are shown in Table. Although ADA activities in all the hepatitis groups are higher than the control group (p<0.05), no difference in ADA levels was found amongst hepatitis groups (p>0.05). However, GDA levels in hepatitis A group was not different from the control group.
DISCUSSION
Increased serum ADA activities have been observed in many infectious diseases caused by microorganisms infecting mainly the macrophages, in tuberculosis, leprosy, visceral and cutaneous leishmaniasis, brucellosis and, in human deficiency virus (HIV) infection (Gakis et al. 1989 , Valls et al. 1990 , Erel et al. 1998 . It was reported that 95% of serologically positive typhoid fever cases found to have increased ADA activity (Ungerer et al. 1996) .
Two ADA isozymes are known as ADA1 and ADA2. While human tissue extracts contained ADA1 predominantly, ADA2 was the main component of serum ADA. Therefore, ADA activity measured in serum reflects ADA2 activity. In the report of Kobayashi et al. (1993) it was found that the ADA2:ADA ratio decreased in acute hepatitis, but increased in chronic active hepatitis and liver cirrhosis.
In our opinion, the elevated serum ADA activity in patients with hepatitis may be reflect of ph-agocytic activity of macrophages, and may provide useful additional diagnostic information on the pathogenesis of hepatitis. For instance, it is known that editing of antigenomic RNA, generates two distinct forms of delta antigen, is involved in ADA activity (Casey & Gerin 1995 , Monjardino 1996 . Since hepatitis delta virus (HDV) is a unique human pathogen associated with hepatitis B infection and molecular pathogenicity of HDV remains to be excluded, the evaluation of ADA activity in sera of patients with hepatitis should be considered as a useful tool to monitorize their clinic. Barnes et al. (1995) reported that adenosine could lessen the potentially damaging activity of neutrophiles at sites of infections. On the other hand, ADA activity counteracts with adenosine by utilizing it. Therefore, development of some ADA inducer drugs or its direct administration may be studied in the future to lessen the risk of chronic liver disease due to hepatitis. In early studies on ADA activity in sera of active and chronic liver diseases, it was suggested that monitorizing of ADA levels in PBMC may show biochemical and/ or histological remission in chronic liver diseases (Nardiello et al. 1983) . However, in our study, no difference in ADA levels was found between acute and chronic hepatitis B cases.
Preliminary results of Jones et al. (1983) suggested that GDA increased in hepatitis and in patients with liver metastases, but normalized in all other liver diseases including cirrhosis and obstructive jaundice. However, we could not observe any statistical difference between acute and chronic hepatitis B cases. Then, we would be able to suggest that GDA might be useful as a indicator for liver condition in hepatitis disease. Since its activity in hepatitis A group is as much as in the control group, it may be an explanatory point for the mechanism results in further liver destruction in chronic forms of HBC and HBV hepatitis.
To explain the cause and mechanisms of increased levels of ADA and GDA activities further studies are needed. 
